Ruben A Mesa MD FACP

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

President, Levine Cancer Institute & Enterprise Cancer Service Line Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center Enterprise Senior Vice President, Atrium Health Vice Dean for Cancer Programs, Wake Forest University School of Medicine Professor of Medicine, Wake Forest University School of Medicine

Join to View Full Profile

1021 Morehead Medical DrSte ACharlotte, NC 28204
Phone+1 980-442-2000

Summary

Dr. Ruben Mesa is a hematologist, and leads cancer efforts for Atrium Health as President of Levine Cancer Institute and Executive Director of Atrium Health Wake Forest Baptist Comprehensive Cancer Center. He specializes in myeloproliferative neoplasms, drug development and health equity research

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1998 - 2002
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1995 - 1998
Mayo Clinic College of MedicineClass of 1995

Certifications & Licensure

AZ State Medical License 2009 - 2027
NC State Medical License 2023 - 2026
TX State Medical License 2017 - 2026
MN State Medical License 1996 - 2013
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2013-2014
Top Doctors:Arizona State Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2012-2013
Fellow (FACP) American College of Physicians, 2007
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia Start of enrollment: 2002 Aug 01
Completed
Phase 2
Azacitidine in Treating Patients With Myelofibrosis Start of enrollment: 2006 Aug 01
Terminated
Phase 2
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders Start of enrollment: 2005 Sep 01
Completed
Early Phase 1
Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia Start of enrollment: 2004 Oct 01
Completed
Phase 2
Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura Start of enrollment: 2007 Jan 01
Completed
Early Phase 1
Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis Start of enrollment: 2008 Mar 01
Terminated
Phase 2
Correlative Biomarker Study in Patients With Myeloproliferative Disorders Start of enrollment: 2007 Apr 01
Completed
CC-4047 in Treating Patients With Myelofibrosis Start of enrollment: 2008 May 01
Completed
Phase 1, Phase 2
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Start of enrollment: 2008 Aug 01
Completed
Phase 1, Phase 2
Azacitidine and Lenalidomide for Acute Myeloid Leukemia Start of enrollment: 2010 Apr 01
Completed
Phase 1, Phase 2
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Start of enrollment: 2011 Sep 01
Completed
Phase 3
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF Start of enrollment: 2011 Jun 01
Completed
Phase 1, Phase 2
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis Start of enrollment: 2013 Oct 01
Completed
Phase 2
Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML Start of enrollment: 2014 Feb 01
Completed
Phase 1, Phase 2
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
COMPLETED
PHASE1
MPN-RC 118 AVID200 in Myelofibrosis Start of enrollment: 2019 Feb 15
Completed
Phase 1
Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation Start of enrollment: 2021 Jan 14
COMPLETED
PHASE2
Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance Start of enrollment: 2020 Aug 25
ACTIVE_NOT_RECRUITING
PHASE3
Calm for Cancer Patients Receiving Chemotherapy Start of enrollment: 2022 Feb 01
Withdrawn
Not Applicable
Join now to see all

Publications & Presentations

PubMed

Patient-Reported Outcomes and Provider Perceptions of Systemic Mastocytosis: Results From the PRISM Study.
Massimo Triggiani, Jessica Hobart, Iván Alvarez-Twose, Cristina Bulai Livideanu, Franziska Ruëff
Clinical and Experimental Allergy. 2025-09-01
Longitudinal graphics of patient-reported physical function in patients treated for hematologic malignancies.
Gita Thanarajasingam, Vishal Bhatnagar, Brie N Noble, Ting-Yu Chen, Mallorie H Fiero
BMC Medical Research Methodology. 2025-08-07
Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.
Haifa Kathrin Al-Ali, Paola Guglielmelli, Claire N Harrison, Ruben A Mesa, J E Hamer-Maansson
Acta Haematologica. 2025-07-18

Abstracts/Posters

Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...
Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms
Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermedi...
Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
Ruben A. Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
Ruben A. Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Patient-Reported Outcomes (PRO) Data from Patients (Pts) with Essential Thrombocythemia (ET) Enrolled in the MOST Study
Ruben A. Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia
Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all

Lectures

SOHO 2020: Bringing 'MPN Awareness' to Hematology Community
Mayo School of Continuous Professional Development, Phoenix, Arizona - 9/14/2013
Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor_Na¥ve Myelofibrosis Patients Treated with Momelo...
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Proposal of an endpoint for a phase III clinical study of essential thrombocythemia: Balancing between short term effects and long term benefits.
2019 ASCO Annual Meeting - 6/1/2019
As If Myeloproliferative Neoplasms Weren't Already Challenging Enough
60th American Society of Hematology Annual Meeting - 12/2/2018
Social Media for the Hematologist: Today and in the Future
60th American Society of Hematology Annual Meeting - 12/2/2018
As If Myeloproliferative Neoplasms Weren't Already Challenging Enough
60th American Society of Hematology Annual Meeting - 12/1/2018
Social Media for the Hematologist: Today and in the Future
60th American Society of Hematology Annual Meeting - 12/1/2018
Real-World Risk Assessment and Treatment of Patients with Myelofibrosis at Community Oncology Practices in the United StatesClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intole...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Characteristics Associated with Hydroxyurea Treatment Change in Patients with Polycythemia Vera: An Analysis from the Reveal Study
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Correlation between MPN-SAF TSS and EORTC QLQ-C30 Scores in Patients with PV: Data from the Reveal StudyClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
A phase 2, multicenter, open-label study of the safety and efficacy of luspatercept in subjects with myeloproliferative neoplasm (MPN)-associated myelofibrosis and ane...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Authored Content

Watch: Momelotinib for Myelofibrosis — Top 10 Takeaways Physicians Should Know Post-FDA approvalSeptember 2023
ASH 2020: An Explosion of Options for MPNs ForthcomingDecember 2020

Press Mentions

‘The Advocate Way’: A New Model for Systemwide Cancer Care IntegrationSeptember 8th, 2025
Diagnostics, AI, Access: Cancer Care Areas Ripe for Innovation, Per 6 LeadersJuly 28th, 2025
5 Cancer Services with Big Patient Results, Per LeadersJuly 14th, 2025
Join now to see all

Grant Support

Consumer-based meditation app, Calm, for treatment of sleep disturbance in hematological cancer patientsUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2022–2027
Administrative Supplement for Assessing and Enhancing Survivorship CareWAKE FOREST UNIVERSITY HEALTH SCIENCES1997–2027
Cancer Center Support GrantWAKE FOREST UNIVERSITY HEALTH SCIENCES1997–2027
Cancer Center Support GrantWAKE FOREST UNIVERSITY HEALTH SCIENCES1997–2027
Cancer Center Support GrantWAKE FOREST UNIVERSITY HEALTH SCIENCES1997–2027
Apoptosis In Myelofibrosis With Myeloid MetaplasiaNational Cancer Institute2004–2006
Apoptosis In Myelofibrosis With Myeloid MetaplasiaNational Cancer Institute2002–2003
Truncated C-Erbb Receptors In Ovarian CarcinomasNational Cancer Institute1992